TY - JOUR
T1 - Dynamics of anti-Spike IgG antibody level after the second BNT162b2 COVID-19 vaccination in health care workers
AU - Ikezaki, Hiroaki
AU - Nomura, Hideyuki
AU - Shimono, Nobuyuki
N1 - Funding Information:
The authors thank Ms. Ryoko Nakashima for managing the dataset and Drs. Kahori Miyoshi, Yuichi Hara, Jun Hayashi, and Hiroshi Hara for scientific advice.
Publisher Copyright:
© 2022 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases
PY - 2022/6
Y1 - 2022/6
N2 - Introduction: Many countries are administering a third dose of COVID-19 vaccines, but the evaluation of vaccine-induced immunity is insufficient. In addition, there are few reports of long-term observation of anti-spike IgG antibody titers after the vaccination in the Japanese population. This study aimed to evaluate anti-spike IgG levels in the Japanese health care workers six months after the BNT162b2 vaccination. Methods: Dynamics of anti-spike IgG levels were assessed over a six-month period following the second vaccination in 49 participants (Analysis-1). A cross-sectional assessment of anti-spike IgG levels six months after the second vaccination was performed in 373 participants (Analysis-2). Results: In Analysis-1, the geometric mean titer of anti-spike IgG was lower in the older age group and decreased consistently after the second vaccination regardless of age. In Analysis-2, the anti-spike IgG level was significantly negatively associated with age (r = −0.35, p < 0.01). This correlation remained statistically significant (r = −0.28, p < 0.01) after adjustment for sex, BMI, smoking habits, alcohol drinking habits, allergies, and fever or other adverse reactions at the time of vaccination. Additionally, participants who drank alcohol daily had significantly lower anti-spike IgG levels than participants who had never drunk alcohol. Sex, smoking habits, allergy, and fever and other side effects after vaccination did not show a significant association with anti-spike IgG levels. Conclusions: Six months post-vaccination, the anti-spike IgG level was substantially lower in older persons and daily alcohol drinkers. This may be an indication for an additional vaccine dose for these at-risk categories.
AB - Introduction: Many countries are administering a third dose of COVID-19 vaccines, but the evaluation of vaccine-induced immunity is insufficient. In addition, there are few reports of long-term observation of anti-spike IgG antibody titers after the vaccination in the Japanese population. This study aimed to evaluate anti-spike IgG levels in the Japanese health care workers six months after the BNT162b2 vaccination. Methods: Dynamics of anti-spike IgG levels were assessed over a six-month period following the second vaccination in 49 participants (Analysis-1). A cross-sectional assessment of anti-spike IgG levels six months after the second vaccination was performed in 373 participants (Analysis-2). Results: In Analysis-1, the geometric mean titer of anti-spike IgG was lower in the older age group and decreased consistently after the second vaccination regardless of age. In Analysis-2, the anti-spike IgG level was significantly negatively associated with age (r = −0.35, p < 0.01). This correlation remained statistically significant (r = −0.28, p < 0.01) after adjustment for sex, BMI, smoking habits, alcohol drinking habits, allergies, and fever or other adverse reactions at the time of vaccination. Additionally, participants who drank alcohol daily had significantly lower anti-spike IgG levels than participants who had never drunk alcohol. Sex, smoking habits, allergy, and fever and other side effects after vaccination did not show a significant association with anti-spike IgG levels. Conclusions: Six months post-vaccination, the anti-spike IgG level was substantially lower in older persons and daily alcohol drinkers. This may be an indication for an additional vaccine dose for these at-risk categories.
UR - http://www.scopus.com/inward/record.url?scp=85126100487&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85126100487&partnerID=8YFLogxK
U2 - 10.1016/j.jiac.2022.02.024
DO - 10.1016/j.jiac.2022.02.024
M3 - Article
C2 - 35288023
AN - SCOPUS:85126100487
SN - 1341-321X
VL - 28
SP - 802
EP - 805
JO - Journal of Infection and Chemotherapy
JF - Journal of Infection and Chemotherapy
IS - 6
ER -